Swissray says sales volume grows 54 percent

TriMed Staff | | Health Imaging | Screening
Swissray International Inc.'s sales volume reached a new high during the month of December, improving 54 percent as compared to first quarter sales.

The company says the numbers are attributed directly to 10 new orders for their digital Radiography ddR systems.

University Hospital Health System in Cleveland purchased two ddRModulaire units, while Hackley Hospital in Muskegon, Mich., ordered three ddRModulaire Plus systems.

Additional orders were received from University of Louisville (Ky.) Hospital; Edwards Healthcare System in Naperville, Ill.; St. Joseph's Hospital in Stockton, Calif.; Nacogdoches Memorial Hospital in Nacogdoches, Texas; Scott Memorial Hospital in Scottsburg, Ind.; and Ingalls Memorial Hospital in Tinley Park, Ill.

TriMed Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.